...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Receives US$5 Million Milestone Payment from Newsoara

A little specificity  from Don on the dates of future conferences and publications would be appreciated. Vagueness on timing has always been an issue with ZEN and RVX.

Share
New Message
Please login to post a reply